Natalia Staszko

Natalia Staszko

Auto-generated profile, based on publicly available information

Natalia Staszko

Wrocław Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2024 in Cells
Verified
Journal Article
Open access
PDF file
TGTomasz Górnicki
Tomasz Górnicki
JLJakub Lambrinow
Jakub Lambrinow
MMMonika Mrozowska
Monika Mrozowska
Klaudia KrawczyńskaKlaudia Krawczyńska
Klaudia Krawczyńska
NSNatalia Staszko
Natalia Staszko
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
Epithelial-to-mesenchymal transition (EMT) is a complex cellular process that allows cells to change their phenotype from epithelial to mesenchymal-like. Type 3 EMT occurs during cancer progression. The aim of this study was to investigate the role of RNA-binding motif single-stranded interacting protein 3 (RBMS 3) in the process of EMT. To investigate the impact of RBMS 3 on EMT, we performed immunohistochemical (IHC) reactions on archived paraffin blocks of invasive ductal breast carcinoma (n = 449), allowing us to analyze the correlation in expression between RBMS 3 and common markers of EMT. The IHC results confirmed the association of RBMS 3 with EMT markers. Furthermore, we performed an in vitro study using cellular models of triple negative and HER-2-enriched breast cancer with the overexpression and silencing of RBMS 3. RT-qPCR and Western blot methods were used to detect changes at both the mRNA and protein levels. An invasion assay and confocal microscopy were used to study the migratory potential of cells depending on the RBMS 3 expression. The studies conducted suggest that RBMS 3 may potentially act as an EMT-promoting agent in the most aggressive subtype of breast cancer, triple negative breast cancer (TNBC), but as an EMT suppressor in the HER-2-enriched subtype. The results of this study indicate the complex role of RBMS 3 in regulating the EMT process and present it as a future potential target for personalized therapies and a diagnostic marker in breast cancer.

14 June 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
ABAlicja Biskup
Alicja Biskup
AWAgata WnęK
Agata WnęK
JSJulia Smagowska
Julia Smagowska
NSNatalia Staszko
Natalia Staszko
EKEwa Kala-Kaziszyn
Ewa Kala-Kaziszyn
MSMikołaj Stańko
Mikołaj Stańko
Polycystic Ovary Syndrome (PCOS), increasingly referred to as polyendocrine metabolic ovarian syndrome (PMOS), is a heterogeneous endocrine–metabolic disorder associated with reproductive dysfunction, hyperandrogenism, insulin resistance, and increased cardiometabolic risk. Due to the central role of insulin resistance, insulin-sensitizing therapies such as myo-inositol (MI), D-chiro-inositol (DCI), and metformin have gained growing clinical attention. Evidence from studies published between 2015 and 2026 suggests that MI and DCI may improve insulin sensitivity, hormonal balance, and reproductive outcomes, including menstrual cycle regularity and ovulation. The 40:1 MI/DCI ratio remains the most extensively studied formulation and appears to reflect physiological proportions. Metformin continues to play a key therapeutic role, particularly in women with insulin resistance, overweight, or obesity, while combination therapy with inositols may provide additional benefits in selected cases. However, evidence remains heterogeneous, highlighting the need for further high-quality randomized controlled trials to clarify the long-term efficacy and optimal clinical use of inositols in PCOS/PMOS management.

25 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JSJulia Smagowska
Julia Smagowska
EKEwa Kala-Kaziszyn
Ewa Kala-Kaziszyn
ABAlicja Biskup
Alicja Biskup
AWAgata WnęK
Agata WnęK
NSNatalia Staszko
Natalia Staszko
Background. Surgical extraction of impacted third molars is often followed by pain, edema, and trismus, which may impair oral function and daily activities during early healing. Photobiomodulation therapy, including low-level laser, LED, and polarized polychromatic non-coherent light, has been investigated as a non-invasive adjunct for reducing postoperative morbidity. Bioptron delivers polarized polychromatic non-coherent light, but evidence for its use in oral surgery is limited. Aim. This narrative review evaluates evidence on photobiomodulation in the management of complications after impacted third molar surgery, with emphasis on the role of Bioptron polarized light therapy. Material and methods. A literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, and Google Scholar for publications from 2000 to 2025. Clinical trials, systematic reviews, meta-analyses, and relevant observational studies assessing photobiomodulation, laser therapy, LED therapy, or polarized light therapy in third molar surgery were included. Results. Evidence suggests that photobiomodulation may reduce postoperative pain, edema, and, to a lesser extent, trismus after third molar extraction, with the strongest support for laser and LED-based interventions. Proposed mechanisms include cytochrome c oxidase activation, increased ATP production, modulation of reactive oxygen species and inflammatory mediators, and enhanced wound healing. However, studies show heterogeneity in treatment parameters, timing, sessions, comparators, and outcome assessment. Evidence specifically addressing Bioptron in this indication remains sparse. Conclusions. Photobiomodulation appears safe and potentially useful after third molar surgery, but evidence supporting Bioptron polarized light remains insufficient. Randomized controlled trials with standardized protocols, sham controls, adequate sample sizes, and validated outcomes are needed.

31 December 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
KBKamila Bała
Kamila Bała
NSNatalia Staszko
Natalia Staszko
Total laryngectomy remains the treatment of choice for advanced stages of laryngeal cancer. Voice prostheses are considered by many authors to be the gold standard for restoring speech after total laryngectomy. Their effectiveness has led to their widespread adoption in clinical practice. As a result, the population of patients using such devices is steadily increasing, which is reflected in a growing scientific interest in this area. This trend has generated an expanding number of studies focused on the analysis of potential complications, available treatment methods in this group of patients. The aim of this review is to analyze potential complications and their management options in patients with tracheoesophageal voice prostheses. All authors independently searched the PubMed database using the following keywords: “tracheoesophageal voice prosthesis,” “primary tracheoesophageal puncture,” “tracheoesophageal fistula,” “laryngectomy,” and “voice prosthesis complications.” Particular attention was paid to reflux therapy with proton pump inhibitors and the potential benefits for patients after laryngectomy. Another important issue discussed in the article concerns methods aimed at reducing biofilm formation on voice prostheses, which consequently translates into longer device lifespan. The effectiveness of botulinum toxin type A was compared with surgical treatment in patients with impaired voice due to spasm of the middle and inferior pharyngeal constrictor muscles (PCM). The studies discussed in this article contribute to improving the quality of life of patients with voice prostheses after laryngectomy. Nevertheless, further research is needed to determine the safety and long-term outcomes of the methods used to manage complications.

3 January 2026 in Quality in Sport
Verified
Journal Article
Open access
KBKamila Bała
Kamila Bała
NSNatalia Staszko
Natalia Staszko
The gut microbiota has emerged as an important factor influencing metabolic health of people. Recent research indicates that children with obesity present distinct microbial compositions compared with their normal-weight peers, suggesting a potential role of intestinal microorganisms in the development adiposity. This paper discusses current findings on how dietary patterns, perinatal exposures and inherited microbial traits shape the gut microbiome in childhood. Particular attention is given to taxa associated with metabolic alterations, as well as to microbial metabolites that may influence energy balance and inflammation. Studies linking the gut microbiota to anthropometric measures and early markers of cardiovascular dysfunction highlight its potential value as a diagnostic tool. Understanding these complex host–microbe interactions may contribute to the development of targeted microbiota-based interventions and personalized therapeutic strategies aimed at preventing or treating childhood obesity.

3 January 2026 in Quality in Sport
Verified
Journal Article
Open access
KBKamila Bała
Kamila Bała
NSNatalia Staszko
Natalia Staszko
The gut microbiota has emerged as an important factor influencing metabolic health of people. Recent research indicates that children with obesity present distinct microbial compositions compared with their normal-weight peers, suggesting a potential role of intestinal microorganisms in the development adiposity. This paper discusses current findings on how dietary patterns, perinatal exposures and inherited microbial traits shape the gut microbiome in childhood. Particular attention is given to taxa associated with metabolic alterations, as well as to microbial metabolites that may influence energy balance and inflammation. Studies linking the gut microbiota to anthropometric measures and early markers of cardiovascular dysfunction highlight its potential value as a diagnostic tool. Understanding these complex host–microbe interactions may contribute to the development of targeted microbiota-based interventions and personalized therapeutic strategies aimed at preventing or treating childhood obesity.